Changes in Hong Kong stocks | Insili Intelligence (03696) rose nearly 8%, and the AI pharmaceutical circuit continues to heat up, and the company's BD and PCC output reached record highs

The Zhitong Finance App learned that Insili Intelligence (03696) rose nearly 8%. As of press release, it had risen 7.85% to HK$59.75, with a turnover of HK$363 million.

According to the news, as of the latest data, the total amount of signed cooperation disclosed by Insili Intelligence within 2026 has reached about 7.3 billion US dollars, and the total value of foreign authorized transactions has reached 11 billion US dollars. In terms of AI-driven R&D, Insilicon Intelligence nominated 9 pre-clinical candidate compounds (PCC) in the first nine months of this year, setting a new historical record for the company's annual pipeline output. Lyon believes that the company's business development momentum is still strong, and the AI-driven phase III clinical trial of the candidate Rentosertib in China is the next major clinical verification point.

It is worth mentioning that recently multinational giants are intensifying AI pharmaceuticals to further heat up the circuit. Roche revealed during an investor event that it will promote the construction of independent artificial intelligence laboratories to speed up the discovery of new drugs. Earlier, Novo Nordisk and Eli Lilly also successively disclosed the progress of wet test cooperation. Citi pointed out that Insilon Intelligence is still the first choice for the bank's artificial intelligence drug discovery (AIDD) sub-sector.